# Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

> **NCT06365788** · PHASE2 · RECRUITING · sponsor: **Universitaire Ziekenhuizen KU Leuven** · enrollment: 53 (estimated)

## Conditions studied

- Triple Negative Breast Neoplasms

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Bicalutamide

## Key facts

- **NCT ID:** NCT06365788
- **Lead sponsor:** Universitaire Ziekenhuizen KU Leuven
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-08
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06365788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06365788, "Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT06365788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*